Phase II randomised discontinuation trial of brivanib in patients with advanced solid tumours.

•We performed a phase II randomised discontinuation trial of brivanib in 7 tumour types (soft-tissue sarcomas [STS], ovarian cancer, breast cancer, pancreatic cancer, non-small-cell lung cancer, gastric/esophageal cancer and transitional cell carcinoma).•In 53 randomised patients with STS and fibroblast growth factor (FGF) 2–positive tumours, the median progression-free survival was 2.8 for brivanib and was 1.4 months for placebo (hazard ratio: 0.58, p = 0.08).•Brivanib demonstrated activity in STS and ovarian cancer with an acceptable safety profile.•FGF2 expression (per protocol) is not a predictive biomarker of the efficacy of brivanib.